ArticleFrontiers in pharmacology2026
Diet-induced obesity impairs refeeding responses and downregulates lateral septal GLP-1R in male rats: an effect reversed by weight-loss treatment.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The lateral septum (LS) is a brain area involved in important physiological functions such as reward, stress response, and autonomic regulation. The LS is one of the brain areas with the highest expression of the glucagon-like peptide-1 receptor (GLP-1R), and pharmacological modulation of GLP-1R in the LS affects food intake. However, the relationship between obesity development and LS dysregulation of the GLP-1/GLP-1R system has been poorly studied. Methods: We aimed to investigate whether chronic exposure to a high-fat diet (HFD) from weaning to postnatal day (PND) 62 affects the LS GLP-1 system, LS neurotransmitter content, and post-fasting refeeding behavior in rats. Furthermore, we evaluated LS GLP-1R levels and refeeding behavior after pharmacological (phentermine, an amphetamine derivative) and dietary (switch to control diet) interventions. Results: Our results show that HFD decreases LS GLP-1R protein levels in male rats, while receptor gene expression increases in female rats. Otherwise, chronic exposure to HFD increases LS glutamate content only in female rats. Treatment with phentermine (30 mg/kg/day) and a control diet reduces body weight and fat tissues in obese rats of both sexes. However, in these animals, the re-exposure to fasting resulted in a marked preference for consuming HFD, an effect not observed in obese rats only exposed to a control diet. Finally, LS GLP-1R levels were normalized in obese male rats treated with phentermine plus a control diet or only with a control diet. Conclusion: In conclusion, the chronic exposure to HFD induces sex differences in LS that could be related to pathological mechanisms observed in obesity and to the efficacy of treatment with GLP-1R agonists. Moreover, phentermine, a classic anorectic drug used for short-term weight loss, generates neurobiological adaptations that increase fasting-induced caloric intake, which could be related to the weight regain observed in obese patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.